Fig. 2From: Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational studyPFS curves of Palbociclib and Ribociclib combined endocrine therapy with or without PPIs. (Kaplan meier estimates). ET: endocrine treatment, PFS: progression free survival, PPI: proton pomp inhibitör, CI: confidence interval, HR: hazard ratioBack to article page